Journal
CYTOTHERAPY
Volume 12, Issue 6, Pages 750-763Publisher
ELSEVIER SCI LTD
DOI: 10.3109/14653241003786155
Keywords
acute myeloid leukemia; adoptive immunotherapy; ex vivo expansion; good manufacturing practice; interleukin-2; interleukin-15; natural killer cells; NOD/SCID mice; xenograft
Categories
Funding
- Onco-suisse [OCS-02175-02-2008]
- Stiftung fur Hamatologische Forschung
- Novartis Stiftung [06C84]
- Stiftung zur Krebsbekampfung [226]
- Freiwillige Akademische Gesellschaft
- Krebsliga beider Basel [04/2008]
Ask authors/readers for more resources
Background aims. Alloreactive natural killer (NK) cells are potent effectors of innate anti-tumor defense. The introduction of NK cell-based immunotherapy to current treatment options in acute myeloid leukemia (AML) requires NK cell products with high anti-leukemic efficacy optimized for clinical use. Methods. We describe a good manufacturing practice (GMP)-compliant protocol of large-scale ex vivo expansion of alloreactive NK cells suitable for multiple donor lymphocyte infusions (NK-DLI) in AML. CliniMACS-purified NK cells were cultured in closed air-permeable culture bags with certified culture medium and components approved for human use [human serum, interleukin (IL)-2, IL-15 and anti-CD3 antibody] and with autologous irradiated feeder cells. Results. NK cells (6.0 +/- 1.2 x 10
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available